Physiomics Plc Logo

Physiomics Plc

PYC.L

(0.5)
Stock Price

0,65 GBp

-71.35% ROA

-74.98% ROE

-3.27x PER

Market Cap.

2.040.056,00 GBp

0% DER

0% Yield

-71.25% NPM

Physiomics Plc Stock Analysis

Physiomics Plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Physiomics Plc Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE indicates a negative return (-63.36%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-71.35%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's elevated P/BV ratio (3.11x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

Physiomics Plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Physiomics Plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Physiomics Plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Physiomics Plc Revenue
Year Revenue Growth
2000 0
2002 50.000 100%
2003 62.000 19.35%
2004 205.000 69.76%
2005 113.000 -81.42%
2006 216.000 47.69%
2007 91.000 -137.36%
2008 460.000 80.22%
2009 153.000 -200.65%
2010 53.000 -188.68%
2011 135.306 60.83%
2012 240.000 43.62%
2013 267.903 10.42%
2014 235.486 -13.77%
2015 297.120 20.74%
2016 219.647 -35.27%
2017 428.277 48.71%
2018 718.965 40.43%
2019 799.055 10.02%
2020 799.055 0%
2021 830.266 3.76%
2022 597.354 -38.99%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Physiomics Plc Research and Development Expenses
Year Research and Development Expenses Growth
2000 53.000
2002 58.000 8.62%
2003 7.000 -728.57%
2004 30.000 76.67%
2005 5.000 -500%
2006 131.000 96.18%
2007 111.000 -18.02%
2008 73.000 -52.05%
2009 159.000 54.09%
2010 258.000 38.37%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Physiomics Plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Physiomics Plc EBITDA
Year EBITDA Growth
2000 -127.000
2002 -257.000 50.58%
2003 -227.000 -13.22%
2004 -432.000 47.45%
2005 -480.000 10%
2006 -238.000 -101.68%
2007 -424.000 43.87%
2008 16.000 2750%
2009 -382.000 104.19%
2010 -680.000 43.82%
2011 -564.383 -20.49%
2012 -535.251 -5.44%
2013 -456.327 -17.3%
2014 -407.835 -11.89%
2015 -402.032 -1.44%
2016 -484.127 16.96%
2017 -257.207 -88.22%
2018 -192.355 -33.71%
2019 -124.880 -54.03%
2020 -124.201 -0.55%
2021 -347.979 64.31%
2022 -563.294 38.22%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Physiomics Plc Gross Profit
Year Gross Profit Growth
2000 0
2002 50.000 100%
2003 62.000 19.35%
2004 205.000 69.76%
2005 113.000 -81.42%
2006 216.000 47.69%
2007 91.000 -137.36%
2008 460.000 80.22%
2009 153.000 -200.65%
2010 53.000 -188.68%
2011 135.306 60.83%
2012 240.000 43.62%
2013 267.903 10.42%
2014 235.486 -13.77%
2015 297.120 20.74%
2016 219.647 -35.27%
2017 428.277 48.71%
2018 718.965 40.43%
2019 799.055 10.02%
2020 799.055 0%
2021 830.266 3.76%
2022 597.354 -38.99%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Physiomics Plc Net Profit
Year Net Profit Growth
2000 -142.000
2002 -259.000 45.17%
2003 -225.000 -15.11%
2004 -382.000 41.1%
2005 -480.000 20.42%
2006 -193.000 -148.7%
2007 -434.000 55.53%
2008 25.000 1836%
2009 -368.000 106.79%
2010 -645.000 42.95%
2011 -539.577 -19.54%
2012 -500.571 -7.79%
2013 -425.621 -17.61%
2014 -357.656 -19%
2015 -378.697 5.56%
2016 -400.526 5.45%
2017 -183.341 -118.46%
2018 -104.040 -76.22%
2019 -64.424 -61.49%
2020 -64.424 0%
2021 -253.138 74.55%
2022 -477.257 46.96%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Physiomics Plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 0
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Physiomics Plc Free Cashflow
Year Free Cashflow Growth
2000 -219.000
2002 -214.000 -2.34%
2003 -230.000 6.96%
2004 -446.000 48.43%
2005 -275.000 -62.18%
2006 -391.000 29.67%
2007 -124.000 -215.32%
2008 25.000 596%
2009 -435.000 105.75%
2010 -650.000 33.08%
2011 -553.679 -17.4%
2012 -526.339 -5.19%
2013 -354.104 -48.64%
2014 -393.276 9.96%
2015 -348.704 -12.78%
2016 -444.076 21.48%
2017 -172.123 -158%
2018 -166.973 -3.08%
2019 -121.464 -37.47%
2020 -30.366 -300%
2021 -358.763 91.54%
2022 -273.222 -31.31%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Physiomics Plc Operating Cashflow
Year Operating Cashflow Growth
2000 -153.000
2002 -203.000 24.63%
2003 -218.000 6.88%
2004 -428.000 49.07%
2005 -273.000 -56.78%
2006 -387.000 29.46%
2007 -123.000 -214.63%
2008 26.000 573.08%
2009 -434.000 105.99%
2010 -643.000 32.5%
2011 -551.772 -16.53%
2012 -524.487 -5.2%
2013 -351.507 -49.21%
2014 -392.651 10.48%
2015 -346.869 -13.2%
2016 -437.274 20.67%
2017 -169.797 -157.53%
2018 -143.772 -18.1%
2019 -116.370 -23.55%
2020 -29.093 -300.01%
2021 -349.393 91.67%
2022 -266.587 -31.06%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Physiomics Plc Capital Expenditure
Year Capital Expenditure Growth
2000 66.000
2002 11.000 -500%
2003 12.000 8.33%
2004 18.000 33.33%
2005 2.000 -800%
2006 4.000 50%
2007 1.000 -300%
2008 1.000 0%
2009 1.000 0%
2010 7.000 85.71%
2011 1.907 -267.07%
2012 1.852 -2.97%
2013 2.597 28.69%
2014 625 -315.52%
2015 1.835 65.94%
2016 6.802 73.02%
2017 2.326 -192.43%
2018 23.201 89.97%
2019 5.094 -355.46%
2020 1.274 -300.16%
2021 9.370 86.41%
2022 6.635 -41.22%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Physiomics Plc Equity
Year Equity Growth
2000 130.000
2002 -129.000 200.78%
2003 -354.000 63.56%
2004 413.000 185.71%
2005 -66.000 725.76%
2006 99.000 166.67%
2007 -353.700 127.99%
2008 -85.000 -316.12%
2009 787.000 110.8%
2010 756.000 -4.1%
2011 734.570 -2.92%
2012 255.821 -187.14%
2013 136.487 -87.43%
2014 325.617 58.08%
2015 204.153 -59.5%
2016 328.254 37.81%
2017 690.026 52.43%
2018 607.914 -13.51%
2019 1.314.981 53.77%
2020 1.165.714 -12.8%
2021 974.807 -19.58%
2022 531.720 -83.33%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Physiomics Plc Assets
Year Assets Growth
2000 139.000
2002 79.000 -75.95%
2003 93.000 15.05%
2004 527.000 82.35%
2005 146.000 -260.96%
2006 303.000 51.82%
2007 114.000 -165.79%
2008 275.000 58.55%
2009 922.000 70.17%
2010 868.000 -6.22%
2011 840.099 -3.32%
2012 380.466 -120.81%
2013 244.193 -55.81%
2014 378.865 35.55%
2015 303.311 -24.91%
2016 415.175 26.94%
2017 818.231 49.26%
2018 694.287 -17.85%
2019 1.446.498 52%
2020 1.323.284 -9.31%
2021 1.115.416 -18.64%
2022 674.393 -65.4%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Physiomics Plc Liabilities
Year Liabilities Growth
2000 9.000
2002 208.000 95.67%
2003 447.000 53.47%
2004 114.000 -292.11%
2005 212.000 46.23%
2006 204.000 -3.92%
2007 468.000 56.41%
2008 360.000 -30%
2009 135.000 -166.67%
2010 112.000 -20.54%
2011 105.529 -6.13%
2012 124.645 15.34%
2013 107.706 -15.73%
2014 53.248 -102.27%
2015 99.158 46.3%
2016 86.921 -14.08%
2017 128.205 32.2%
2018 86.373 -48.43%
2019 131.517 34.33%
2020 157.570 16.53%
2021 140.609 -12.06%
2022 142.673 1.45%

Physiomics Plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0
Price to Earning Ratio
-3.27x
Price To Sales Ratio
3.42x
POCF Ratio
-5.85
PFCF Ratio
-7.47
Price to Book Ratio
2.93
EV to Sales
2.72
EV Over EBITDA
-2.88
EV to Operating CashFlow
-6.09
EV to FreeCashFlow
-5.94
Earnings Yield
-0.31
FreeCashFlow Yield
-0.13
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.02
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.56
ROE
-0.63
Return On Assets
-0.57
Return On Capital Employed
-0.79
Net Income per EBT
0.87
EBT Per Ebit
0.98
Ebit per Revenue
-0.84
Effective Tax Rate
0.13

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.06
Gross Profit Margin
-0.84
Operating Profit Margin
-0.84
Pretax Profit Margin
-0.82
Net Profit Margin
-0.71

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0.02
Capex to Revenue
-0.01
Capex to Depreciation
-0.64
Return on Invested Capital
-0.9
Return on Tangible Assets
-0.71
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.74
Current Ratio
4.63
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.01
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Physiomics Plc Dividends
Year Dividends Growth

Physiomics Plc Profile

About Physiomics Plc

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union. It offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour predictive software. The company also develops technology for use in the field of personalized medicine. Physiomics Plc was incorporated in 2001 and is based in Oxford, the United Kingdom.

CEO
Dr. Peter Joseph Sargent
Employee
10
Address
The Magdalen Centre
Oxford, OX4 4GA

Physiomics Plc Executives & BODs

Physiomics Plc Executives & BODs
# Name Age
1 Dr. Peter Joseph Sargent
Chief Executive Officer, Chief Operating Officer & Director
70
2 Dr. Venkata Putcha
Head of Biostatistics
70
3 Mr. Anthony Louis Clayden ACA, BSc (Hons), MSI
Head of Finance & Company Secretary
70
4 Ms. Hayley Close
Head of Business Development
70
5 Dr. Mark Middleton M.D., Ph.D.
Consultant & Member of Scientific Advisory Board
70
6 Dr. Robert Jackson Ph.D.
Consultant & Member of Scientific Advisory Board
70
7 Dr. Christophe D. Chassagnole Ph.D.
Chief Scientific Officer & Executive Director
70
8 Prof. David Fell
Co-Founder & Member of Scientific Advisory Board
70

Physiomics Plc Competitors